The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

Asthma in Children Clinical Trial

Official title:

The Effect of Adding Nebulized Epinephrine in Asthma Exacerbation Management in Pediatric Age Group Compared to Standard of Care: Superiority Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05667727
• Other study ID #: R2016
• Status: Recruiting
• Phase: Phase 4
• Start date: October 15, 2023
• Est. completion date: June 1, 2025

Study information

• Verified date: April 2024
• Source: Oman Medical Speciality Board
• Contact: Adnan Al-Rawahi, Resident
• Phone: 00968 95576483
• Email: r2016[@]resident.omsb.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Our study aiming to look in improvement of Pediatric Respiratory Assessment Measure (PRAM) score as a primary outcome. The secondary outcomes involving the need for second step management, need for admission and possible side effects.

It's double blinded randomized control study comparing Nebulized Epinephrine with standard treatment (salbutamol + Ipratropium) versus the standard treatment only in pediatric patient.

A pilot study will be conducted before to detect the sample size required and data will be collected at deferent interval post treatment targeting intension to treat for analysis.

Description:

Because there are no previous studies with the same methodology found, pilot study will be conducted to estimate the sample size.

Patients who are eligible to be enrolled in the study will be randomized into two group (after receiving the standard of care, 3 back to back nebulization (salbutamol and ipratropium bromide)) , the experimental group will be given epinephrine (1ml of 1:1000) as nebulization and the control group will receive salbutamol nebulization as 4th nebulization.

PRAM score with calculated before and at 60, 80, 100 min after the treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 1, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 13 Years

Eligibility

• Inclusion Criteria:

• Pediatric age group 3 - 12 years

• known to have asthma

• Initial PRAM Score showed moderate to severe asthma exacerbation

• Exclusion Criteria:

• History of lung or upper airway disease other than asthma:

• bronchiolitis, anaphylaxis, pertussis, vocal cord dysfunction, foreign body aspiration, bronchopulmonary dysplasia, cystic fibrosis and lower airway mass effects

• History of congenital heart disease or cardiac arrhythmia or heart failure.

• Known hypertension

• Impending respiratory failure (Decreasing mental status, Respiratory fatigue, Impending respiratory arrest, Hypoxemia (pO2 < 60 mmHg), pCO2 could be normal or high)

• Allergy or hypersensitivity to epinephrine

• Patient/Parents refusal to participate in the study

Related Conditions & MeSH terms

• Asthma
• Asthma in Children
• Dyspnea
• Epinephrine Causing Adverse Effects in Therapeutic Use
• Shortness of Breath

Intervention

Drug:
• nebulized epinephrine
we are using 1:1000 epinephrine into nebulization form
• Salbutamol
Patient will receive salbutamol as 4th nebulization.

Locations

Country	Name	City	State
Oman	Royal Hospital	Muscat

Sponsors (1)

Lead Sponsor	Collaborator
Oman Medical Speciality Board

Country where clinical trial is conducted

Oman, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in pediatric respiratory assessment measure (PRAM) score	treating physician will calculate the PRAM score before and immediately after the intervention by 20 mins, if there is no change in PRAM score or the case worsen, candidate will receive further treatment, but if he/she improved, will be assessed in the second interval.	at (60) mints
Primary	change in pediatric respiratory assessment measure (PRAM) score	immediately after the intervention by 40 mins, candidate will be assessed, calculating the PRAM score again, and decide he/she will need further treatment or to continue observation.	at (80) mints
Primary	change in pediatric respiratory assessment measure (PRAM) score	immediately after the intervention by 90 mins, candidate will be assessed again, calculating the PRAM score and decide about if he will need further treatment or no.; Total observation will be almost 2 hours in order to look for other outcome as well.	at (100) mints
Secondary	Emergency Department (ED) length of stay	"during the assessment", after the exposure; This outcome will be decided upon each reassessment intervals, at any time during assessment if there is no change in PRAM score or worsening patient will receive further treatment as decided before and his enrollment in the study will be ended here.	from the randomization up to 4 hours
Secondary	The rate for admission	"during the assessment"; this will be determined at the disposal plan for each candidate from the emergency department, either admission or discharge home.	from the randomization up to 4 hours
Secondary	rate of any side effect of nebulized epinephrine	"during the assessment"; Each candidate will be assessed throughout the enrolment in the study, starting from the administration of the medication till 2 hours post exposure.	from the randomization up to 4 hours
Secondary	The need for respiratory support (O2, Non-invasive ventilation, intubation)	"during assessment"	from the randomization to the disposal time
Secondary	The rate of revisit to Emergency Department within 72 hours of the index visit	"after discharge"	Till 72 hours post discharge